1.762 hasil
Menampilkan 1–20 · 0,08 detik · RSS
Molecular Oncology
Scopus
ISSN 1878-0261 · Wiley · 1.762 artikel di indeks
-
Artikel Jurnal
Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer
Breast cancer (BC) diagnostics and prognostics traditionally rely on invasive tissue biopsies, presenting limitations for large‐scale screening and continuous patient monitoring. Salivary biomarkers have recently emerged as a compelling noninvasive and accessible alternative, offering significant…
-
Artikel Jurnal
YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma
The rare vascular sarcoma epithelioid hemangioendothelioma (EHE) is defined by WWTR1 or YAP1 gene rearrangements that result in functional fusion proteins. Previous studies have demonstrated the ability of these gene fusions to function as constitutively active TEAD coactivators, while also…
-
Artikel Jurnal
Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer
Deamination of adenosine to inosine (A‐to‐I) in double‐stranded microRNAs (miRNAs) has been demonstrated to affect their function as suppressors or oncogenes in various cancers. Nevertheless, the functional impact of miRNA editing in high‐grade serous ovarian cancer (HGSOC) remains largely…
-
Artikel Jurnal
Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer
Merkel cell carcinoma (MCC) is a highly aggressive disease with the poorest prognosis among skin cancers, originally posited to be derived from Merkel cells. Emerging evidence, however, suggests other potential origins for MCC, including hematological lineages. We utilized targeted and multi‐omics…
-
Artikel Jurnal
β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1
Cisplatin is one of the most used anticancer chemotherapy agents; however, over time, patients develop resistance to the treatment, and survival rates drop dramatically. Investigation of tumor cell resistance mechanisms could increase sensitivity and prevent cancer progression. Here, we…
-
Artikel Jurnal
Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology
Molecular diagnostics has revolutionized cancer management, enabling the identification of diagnostic, prognostic, and predictive biomarkers. Despite advancements in technologies such as whole genome sequencing, their translation into clinical practice remains challenging due to insufficiently…
-
Artikel Jurnal
Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine
Relapsed/refractory (R/R) disease is a major hurdle to long‐term survival of acute myeloid leukemia (AML) patients treated with intensive cytarabine (AraC)‐based chemotherapy. R/R AML salvage treatment with venetoclax (VEN) + azacitidine (AZA) results in overall response rates between 20% and 60%…
-
Artikel Jurnal
Strength through diversity: how cancers thrive when clones cooperate
Cancer is a highly heterogeneous disease, with many cancers containing multiple distinct subclones. While subclones are often seen as competitors (survival of the fittest), intratumor heterogeneity can also offer direct benefits to the tumor through cooperation between different clones. This has…
-
Artikel Jurnal
Emerging role of ARHGAP29 in melanoma cell phenotype switching
Rho GTPase‐activating protein 29 (ARHGAP29) is an inhibitor of the Ras homolog family member A (RhoA)/Rho‐associated protein kinase (ROCK) signaling pathway. Studies in non‐melanoma cancer entities described that ARHGAP29 modulates the actin cytoskeleton, promoting tumor cell invasion. In melanoma…
-
Artikel Jurnal
Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities
The cancer problem is expanding, particularly in low‐ and middle‐income countries (LMICs). Preventive measures can reduce the incidence by 40–50%, and cure rates have increased during the past decades in a number of cancers. However, optimizing prevention programmes and increasing cure rates of…
-
Artikel Jurnal
Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy
Immune checkpoint blockade (ICB) is standard treatment in several cancer types, despite not being proven efficacious in metastatic hormone receptor‐positive breast cancer (HR+ mBC). The gut microbiota is associated with patient outcome and toxicity from cancer therapy, although limited data are…
-
Artikel Jurnal
In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma
Tumor recurrence after local tumor ablation, including high dose rate brachytherapy (HDR‐BT), represents a substantial challenge in hepatocellular carcinoma (HCC) treatment. This study aimed to investigate whether induced factors that appear in patient serum after HDR‐BT alter HCC growth in vitro…
-
Artikel Jurnal
Effect of chemotherapy on passenger mutations in metastatic colorectal cancer
Metastatic colorectal cancer (mCRC), particularly microsatellite stable (MSS) cases, often exhibits limited responsiveness to immunotherapy, leaving chemotherapy as the primary treatment option. While chemotherapy effectively targets tumor cells, its impact on the broader mutational landscape…
-
Artikel Jurnal
PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer
Prostate cancer (PCa) is the second most lethal cancer in men in the US. African American (AA) men have twice the incidence and death rate of European American (EA) men. Advanced PCa shows increased expression and activity of the DNA damage/repair pathway enzyme, poly (ADP‐ribose) polymerase 1…
-
Artikel Jurnal
Molecular characterisation of human penile carcinoma and generation of paired epithelial primary cell lines
Penile carcinoma is a rare malignancy in developed countries but is more common in South America and East Africa. The small number of cases means there are limited resources to investigate disease pathogenesis. This report describes a method of generating primary cell lines from freshly isolated…
-
Artikel Jurnal
PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism
Despite significant advancements, multiple myeloma (MM) remains incurable, largely due to drug resistance. Our previous research has demonstrated that proline metabolism plays a role in MM progression and that inhibiting PYCR1, the final enzyme in proline synthesis, enhances bortezomib sensitivity…
-
Artikel Jurnal
Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism
Glioma stem cells (GSCs) from this aggressive brain cancer have been subject to nononcogene addiction therapeutic strategies, in particular targeting iron and cholesterol metabolic pathways. In this study, we show the small molecule Adaptaquin (AQ) has anti‐GSC effects while sparing neurons, mature…
-
Artikel Jurnal
Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling
Kinase inhibitors have achieved great success in targeted cancer therapy, yet the evident limitations in their effectiveness persist due to therapeutic resistance. To gain insight into the molecular mechanisms and thwart resistance, we profiled the time‐resolved nascent protein perturbations in…
-
Artikel Jurnal
Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity
Colorectal cancer (CRC) represents the third leading cause of cancer‐related deaths. Integrating cellular and molecular data from individual patients has become valuable for diagnosis, prognosis, and treatment selection. Here, we present a comparative mRNA‐seq analysis of tissue samples from 32 CRC…
-
Artikel Jurnal
Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia
Despite promising anti‐leukemic activity of MCL‐1 inhibitors in preclinical studies of acute myeloid leukemia (AML), clinical progress has been hindered by limited knowledge of target patient subgroups. To stratify patients for MCL‐1 inhibitor treatment, we evaluated the sensitivity of 42 primary…
Menampilkan maksimal 50 halaman. Persempit pencarian dengan filter untuk hasil yang lebih spesifik.